New Zealand markets closed

Terumo Corporation (4543.T)

Tokyo - Tokyo Delayed price. Currency in JPY
Add to watchlist
2,634.50+9.50 (+0.36%)
At close: 03:15PM JST
Full screen
Previous close2,625.00
Open2,582.50
Bid2,633.00 x 0
Ask2,636.50 x 0
Day's range2,566.00 - 2,636.00
52-week range1,856.00 - 3,014.50
Volume4,540,900
Avg. volume3,159,711
Market cap3.912T
Beta (5Y monthly)0.47
PE ratio (TTM)36.90
EPS (TTM)71.40
Earnings date07 Aug 2024 - 12 Aug 2024
Forward dividend & yield26.00 (0.99%)
Ex-dividend date27 Sept 2024
1y target est3,105.00
  • Business Wire

    MicroVention Announces the Next Evolution in Stent Innovation: MicroVention’s LVIS™ EVO™ Intraluminal Support Device Now Available in the United States

    ALISO VIEJO, Calif., June 26, 2024--MicroVention, Inc., a global neurovascular company and wholly owned subsidiary of Terumo Corporation, today announced that the LVIS™ EVO™ Intraluminal Support Device is now commercially available in the United States for the treatment of wide neck intracranial aneurysms. LVIS EVO has been available in Europe since 2019 and over 12,000 units have been sold. LVIS EVO is the first fully visible coil-assist-intracranial stent available in the US Market.

  • PR Newswire

    Terumo Cardiovascular Announces 510(K) Clearance for the CDI OneView™ Monitoring System

    Terumo Cardiovascular, a global leader in cardiovascular surgery technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the CDI OneView Monitoring System. The next-generation CDI Systems platform provides visibility of key patient parameters during cardiopulmonary bypass surgery, critical to perfusion safety and improving patient outcomes.

  • PR Newswire

    FDA Clears the Individualized Nomogram for Rika Plasma Donation System

    Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company, recently received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Rika Plasma Donation System™ with the iNomi™ Nomogram. This innovation means that plasma collection volume can be determined by an individual donor's height, weight and hematocrit level on the day they donate plasma.